This profile has not been claimed and data may not be accurate.
89th percentile
42nd percentile
Founder Matrix
Most Like You
Most Complimentary
Credibility
Traction · 90th percentile
- Ginkgo Bioworks raised over $700M in total venture funding.
- Ginkgo Bioworks went public via IPO in 2021 at a $15 billion pre-money valuation.
- Warp Drive was acquired by Ginkgo Bioworks.
- Gen9 was acquired by Ginkgo Bioworks.
Founder score
- 98%Probability of being accurate (98%)Current co-founder and CTO of Ginkgo Bioworks.
- 97%Probability of being accurate (97%)Ginkgo Bioworks went public via IPO in 2021 at a $15 billion pre-money valuation.
- 95%Probability of being accurate (95%)Ginkgo Bioworks is a Y Combinator Summer 2014 alum.
- 95%Probability of being accurate (95%)Ginkgo Bioworks was co-founded with Austin Che, Reshma Shetty, Jason Kelly, and Barry Canton.
- 92%Probability of being accurate (92%)Ginkgo Bioworks raised over $700M in total venture funding.
- 82%Probability of being accurate (82%)Identified as a researcher on OpenAlex with 1,065 citations across 9 works in biological engineering.
- 80%Probability of being accurate (80%)Warp Drive was acquired by Ginkgo Bioworks.
- 80%Probability of being accurate (80%)Gen9 was acquired by Ginkgo Bioworks.
Investor score
- 65%Probability of being accurate (65%)Made at least one known investment in Motif Foodworks.
What you likely need
Barry Canton is a high-profile biotech co-founder whose company Ginkgo Bioworks went public at a $15B valuation after raising $700M — placing him firmly in the top tier of deep-tech founders. His current focus appears to be scaling Ginkgo's autonomous lab and cloud biology platform, with significant technical credibility from his MIT PhD and ongoing research output. Strengthening his public investor and advisory profile could amplify his influence beyond Ginkgo.
Are these your current priorities?
We will tune and customize your Founder Festival experience to make sure you get invited to the events that would be most valuable to you.
- positioningFormalize your angel investing activity by building a public portfolio page or joining a recognized syndicate, given your deep biotech network and Ginkgo's ecosystem of spinouts.
- introsPursue board or advisory seats at synthetic biology and biotech startups to extend your influence and create deal flow aligned with Ginkgo's platform strategy.
- tacticalOpen-source some of Ginkgo's internal bioinformatics or lab-automation tooling on GitHub to build developer community around the cloud lab platform.
- positioningIncrease visibility at synthetic biology and AI-for-science conferences (e.g., SynBioBeta, ISEF, NeurIPS Bio workshops) to position Ginkgo's cloud lab as the default autonomous biology infrastructure.
- hiringPublish more peer-reviewed work or preprints on Ginkgo's autonomous lab and cell-free protein synthesis results to strengthen academic credibility and attract top scientific talent.
- introsLeverage your YC S14 alumni network to identify early-stage biotech founders who could benefit from Ginkgo Cloud Lab as their first lab infrastructure.
- wellbeingAs a public-company co-founder navigating a challenging biotech market, consider structured peer support with other post-IPO founders to manage the unique pressures of the public-company transition.